Clinical trial NCT03980561
Conditions: Cannabis Use Disorder
Keywords: marijuana substance use
Sponsor: Medical University of South Carolina
Start date: 2020-01-31; Completion date: 2023-12-01
Enrollment: 174 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

Detailed description:

Arms: arm 1: 2 mg daily arm 2: 2 mg daily
Interventions: intervention 1: Varenicline intervention 2: Placebo
Intervention descriptions: intervention 1: Active medication intervention 2: Inactive medication

Protocol documents:
Prot_SAP_001.pdf: 
Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
Varenicline for the Treatment of DSM 5 Cannabis Use Disorder in Adults 
 
Study Overview and Design 
Although cannabis use is widespread and basic science research on cannabinoids is well-developed, 
advancements in medication development for cannabis use disorder (CUD) have been limited. Varenicline, a 
selective nicotinic nACH receptor partial agonist of the α4β2 subtype and a full agonist of the α7 subtype, is 
arguably the most effective pharmacotherapy for promoting tobacco abstinence, and has also shown promise 
for the treatment of alcohol use disorder. Varenicline may improve cannabis use outcomes through multiple 
mechanisms, including interaction with the mesolimbic dopamine system, enhancement of cognitive functioning, 
and restoration of inhibitory control. To date, however, varenicline has not been evaluated in individuals 
specifically seeking treatment for CUD. Through the UG3/UH3 mechanism we proposed to rapidly yet thoroughly 
assess the utility of varenicline for CUD to potentially advance varenicline through the FDA’s drug development 
approval pipeline. In the UG3 component, we conducted a six-week, placebo-controlled proof-of-concept clinical 
trial of varenicline for CUD, paired with pre- and post-evaluations of cognitive functioning and neural circuitry 
involved in cannabis cue reactivity and inhibitory control to elucidate the pharmacodynamics of varenicline as a 
treatment for CUD.  We successfully met the pre-specified Go/No Go criteria for the UG3 study. For the the UH3 
component, we will extend our promising UG3 findings by conducting a 12-week, placebo-controlled, double-
blind trial to determine the impact of varenicline on cannabis use outcomes.  
 
Specific Aim 1. To evaluate the efficacy of varenicline for cannabis use disorder (CUD). Hypothesis 1: A 12-
week treatment course of varenicline, compared to placebo, for CUD will yield significant reduction in cannabis 
use. 
 
Specific Aim 2. To examine the safety and tolerability of varenicline, compared with placebo, when used for 
CUD. Hypothesis 2: A 12-week treatment course of varenicline, compared to placebo, will demonstrate 
adequate safety and tolerability, as defined by non-inferiority in the frequency of treatment-emergent adverse 
events.  
 
Exploratory Aim. To evaluate the effect of varenicline on negative affect, and the relationship between negative 
affect and cannabis use reduction, during CUD treatment. Exploratory Hypothesis 1: A 12-week treatment 
course of varenicline, compared to placebo, for CUD will yield reduction in negative affect. Exploratory 
Hypothesis 2: Reduction in negative affect during varenicline treatment will be associated with cannabis use 
reduction. 
 
Participants. A total of approximately180 participants with CUD, aged 18 and over, will be recruited over a 32-
month period at 2 participating sites.  
Inclusion Criteria  
• Meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days per week in the last 30 
days. 
• Express interest in receiving treatment for cannabis use disorder and reducing use. 
• Males and females at least 18 years of age.  
• If female and of childbearing potential, must agree to use acceptable methods of birth control for the 
duration of the trial. 
• Must consent to random assignment, and be willing to commit to medication ingestion. 
• Must be able to read and provide informed consent. 
• Must have body weight >110lbs (50kg) and have BMI between 18 and 35 kg/m2 
• Must function at an intellectual level and have knowledge of the English language to sufficiently allow for 
accurate completion of assessments. 
 
Exclusion Criteria 
• Women who are pregnant, nursing, or plan to become pregnant during the course of the study. 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
• Individuals with severe renal impairment (creatinine clearance less than 30 mL per minute). 
• Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic disorder.  Stably treated 
MDD, Dysthymia, GAD, Social Phobia, and Specific Phobia diagnoses are acceptable (i.e. same dose of 
medication has been prescribed for at least 2 months prior to screening and no changes in current 
medication expected during course of the trial). 
• Past year or current posttraumatic stress disorder. 
• Subjects who are actively suicidal, or who report suicidal ideation (SI) with intent or plan in the past year.  
• Subjects who have a SBQ-R total score ≥8, or for whom the investigator judges that a risk assessment 
by a qualified medical professional is required. Subjects answering ‘yes’ on questions 4 or 5 of C-SSRS 
will be referred to assessment by a qualified mental health professional. 
• Suicidal behavior within the past 10 years or a lifetime history of serious or recurrent suicidal behavior.  
• Subjects who are believed to be at homicidal risk.  
• Concomitant use of psychotropic medications, with the exception of stable doses (defined as no dosing 
adjustments in the past two months) of non-MAO-I antidepressants, non-benzodiazepine anxiolytics, and 
ADHD medications. 
• Current use of medications prescribed for mania or psychosis. 
• Current use of bupropion or nortryptiline. 
• Moderate or severe non-cannabis substance use disorders within the past 60 days with the exception of 
tobacco use disorder. 
• Past year or current moderate or severe alcohol use disorder. 
• Individuals taking an investigational agent within the last 30 days before baseline visit. 
• Individuals with clinically significant medical disorders or lab abnormalities. 
• Any individual at screening with SGOT (AST) or SGPT (ALT) greater than 3 times the upper limit of normal 
and/or total bilirubin greater than two times the upper limit of normal. 
• Individuals with clinically significant cardiovascular disease in the past 6 months (e.g., myocardial 
infarction, CABG, PTCA, severe or unstable angina, serious arrhythmia, or any clinically significant ECG 
conduction abnormality) 
•  Individuals with clinically significant cerebrovascular disease in the past 6 months such as TIA, CVA, or 
stroke 
• Hypersensitivity to varenicline.  
• Individuals who have participated in the clinical trial of any investigational agent within the last 60 days. 
• Individuals who are on probation or under a mandate to obtain treatment. 
• Individuals with plans to initiate or change frequency of attendance at self-help meetings (e.g. AA, NA). 
 
Recruitment. Recruitment is planned to occur through both clinical referral and advertising.  
Procedures. 
Strategies to Ensure a Robust and Unbiased Approach: As detailed throughout this section, the proposed study 
will achieve robust and unbiased results via several design features including: explicit inclusion/exclusion criteria; 
randomization of treatment condition; placebo control; blinding; use of validated measures and methods; explicit 
hypotheses and corresponding planned statistical analyses; power estimates; planned handling of 
retention/attrition and missing data; objective adherence monitoring; and careful consideration of potential 
confounds.  
Screening and Eligibility Assessment. Individuals will be screened by the research study intake coordinator. The 
consent and all screening/eligibility procedures may be completed remotely, via a secure Web-based platform 
such as Doxy.me or RedCap, or a combination of these platforms as appropriate.  A quick screen, focused on 
inclusion/exclusion psychiatric diagnoses, medical status, current medication regimen, and ability and 
willingness to commit to completion of study procedures, will be used to initially determine study eligibility. 
Interested individuals will be given a full description of the study procedures and asked to read and sign an IRB-
approved informed consent form. In order to confirm and document understanding, individuals will be asked to 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
complete a consent quiz prior to signing the form.  They will also be asked to complete a W9 during the informed 
consent/teleconsent process. 
Diagnostic/Descriptive Assessment. The MINI International Neuropsychiatric Interview (MINI) will be used to 
assess psychiatric and substance use diagnoses. A detailed medical history will be taken, and subjects will be 
asked to complete bloodwork at the MUSC CNL or a local LabCorp of their choosing (or AnMed lab in Pickens) 
to ensure the individual is eligible to participate.  A physical exam will be conducted only if there is an issue 
raised by either the medical history or bloodwork. In the event that an individual is found to be ineligible to 
participate in this research protocol, he or she will be given an appropriate referral for further medical care or to 
an appropriate treatment program. 
Treatment Assignment. Individuals who meet all inclusion criteria and no exclusion criteria will be randomized to 
receive either varenicline or matching placebo. Randomization (stratified on tobacco smoking status and gender) 
and dispensing will be performed by the MUSC Investigational Drug Service. Varenicline will be provided at the 
standard recommended dose of 0.5mg daily for three days, then 0.5mg twice daily for four days, and then 1mg 
twice daily for the remainder of the 12-week treatment period.  Matching placebo and varnicline (0.5mg and 1mg) 
capsules will be compounded by IDS utilizing Letco 00 capsules and microcrystalline cellulose filler.  For the 
Pickens site, medication will be packaged and dispensed by MUSC IDS, and then shipped to Pickens via 
registered courier. On site, medication will be stored in a controlled access environment and provided to 
participants by appropriately trained and designated study staff, with double checks in place. In extenuating or 
emergency circumstances, when patient visits are not feasible or are prohibited, such as in the case of a 
pandemic, weekly medication may be mailed to participants. 
Medication Management. Medication Management (MM) is a common-sense, generalizable approach to 
encourage adherence to medication specifically, and to a treatment plan in general. Once a week, participants 
will be seen for a brief MM session. Sessions will be focused on (a) developing and maintaining rapport, (b) 
reviewing AEs and concomitant medications, and (c) discussing progress with medication adherence and 
cannabis reduction/abstinence. These sessions provide an opportunity to address challenges and help 
participants devise strategies for success. A similar intervention was utilized in the NIDA-funded CTN0053 trial 
(Achieving Cannabis Cessation—Evaluating N-Acetylcysteine Treatment) to provide an evidence-based 
treatment platform for all participants. MM with participants at the Pickens site will be done by approved medical 
personnel there and, as needed, by MUSC site medical personnel via WebEx or Doxy.me, HIPAA-compliant, 
MUSC Information Security-approved platforms for telehealth. In extenuating or emergency circumstances, 
when patient visits are not feasible, safe, or are prohibited, such as in the case of a pandemic, MM at both sites 
may be completed remotely by telehealth/phone. 
Assessments. Table 4 provides an overview of assessments; a brief description of the instruments is provided 
below.  In extenuating or emergency circumstances, when patient visits are not feasible, safe, or are prohibited, 
such as in the case of a pandemic, visits and their procedures that can be completed remotely by 
telehealth/phone may be.  Additionally, urine drug and cotinine tests may be completed less than weekly if 
deemed appropriate. All of the assessments will mirror what would be done in clinic, and as such do not add risk 
to the participants. 
 
Table 6. Schedule of assessments. 
 
Scr
een
ing 
BL 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
5 
Wk 
6 
Wk 
7 
Wk 
8 
Wk  
9 
Wk 
10 
Wk 
11  
Wk 
12 
FU
1 
Quick Screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine pregnancy test 
X 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
C-SSRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
SBQ-R 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Daily Substance Use 
Logs and Time-Line 
Follow-Back 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
MCQ 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urine Drug Test 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urine cotinine 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
CWS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
PROMIS-29 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
DSM-5 Criteria for 
CUD 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
Self-Efficacy 
Questionnaire 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Marijuana Problem 
Scale 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Reasons for Quitting 
Questionnaire 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of AEs 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pill Count 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Med Video 
Adherence 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Screening and Diagnostic Instruments. Quick Screen: This assessment will be used to quickly determine 
whether an individual meets inclusion or exclusion criteria for the study when they first present. The instrument 
is designed to assess for substance dependence and obvious psychiatric, medical, and logistic exclusions. Mini-
International Neuropsychiatric Interview (M.I.N.I.): The M.I.N.I. is a brief structured interview that was 
designed to assess DSM-5 diagnoses using a series of questions in dichotomous format (yes/no) (Sheehan & 
Lecrubier, 2003; Sheehan et al, 1998).  
 
Psychiatric and Functioning Assessments. Columbia-Suicide Severity Rating Scale (C-SSRS): The C-SSRS 
(Posner et al., 2011) is a brief, low-burden suicide assessment scale administered by a clinician. We have 
successfully used this instrument in multiple previous trials, and it is regarded as the gold standard of suicidality 
assessment in clinical trials. Suicide Behaviors Questionnaire-Revised (SBQ-R): The SBQ-R is a 4-item 
psychological self-report questionnaire designed to identify risk factors for suicide by assessing different 
dimensions of suicidality including lifetime suicide ideation and/or attempt, frequency of suicidal ideation over 
past 12 months, threat of suicide attempt, and likelihood of suicidal behavior in the future. PROMIS-29: This 
assessment, available through the Phen-X toolkit, includes 29 self-administered quality of life-type questions 
from the PROMIS® Profile 29 for adults. The quality of life questions include physical function, anxiety, 
depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain intensity over 
the past 7 days. Each question, except for the pain intensity question, is measured on a 5-point scale.   
 
Daily Substance Use Logs. Participants will be asked to complete daily report surveys through REDCap 
(Research Electronic Data Capture –  a secure, web-based application designed exclusively to support data 
capture for research studies) during the study. The daily report will ask about cannabis and any other drug or 
alcohol use on the day prior, as well as (during the 12 weeks of treatment) times of medication dosing. 
Participants will be asked to begin completing daily reports following their screening visit. Links to access the 
daily report will be sent to participants through their mobile phone and their email address.  Participants may 
complete daily reports on either their smartphone or on a computer. 
 
Substance-Related Instruments. Time-Line Follow-Back (TLFB): The TLFB (Sobell & Sobell, 1992) is a 
calendar-based instrument designed to assess daily substance consumption. Although initially designed to 
assess alcohol use, we have successfully modified this instrument to assess for other drug use. Upon review of 
the participant’s daily substance use logs, cannabis use will be recorded as times used per day, with each time 
being defined as cannabis use separated by an hour of no cannabis use, in order to standardize for different 
types of cannabis use (joints, bowls, blunts, etc.), as well as recorded as amount used per day. Nicotine and 
other substance use will also be assessed. Urine Drug Testing: The urine drug tests will be screened 
qualitatively for the presence of opioids, cocaine, amphetamines, and benzodiazepines. Urine cannabinoid tests 
will be performed using the AXSSYM® system from Abbott Laboratories. This assay is semi-quantitative with a 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
detection cut-off value of 30.00 ng/ml (Abbott AXSSYM® System package insert). Urine creatinine will also be 
obtained, as creatinine normalization has been proposed as a method to differentiate new cannabis use from 
residual drug excretion (Huestis and Cone, 1998; Schwilke et al, 2011). Urine Cotinine: Nicotine is metabolized 
to cotinine by the liver. Cotinine has a longer half-life than nicotine, and thus serves as a more reliable biomarker 
of cigarette smoking (Zevin et al., 2000). Urine will be screened qualitatively at each visit (detection cut-off value 
of 200 ng/ml). Marijuana Craving Questionnaire (MCQ): The MCQ (Heishman et al, 2001) is a Likert-based 
self-assessment of cannabis craving shown to be a valid and reliable instrument for measuring cannabis craving. 
The 12-item MCQ will be used, which has been constructed by selecting the three items from each factor of the 
full 47-item MCQ that exhibited the most within-factor reliability (Heishman et al, 2009). Cannabis Withdrawal 
Scale: The Cannabis Withdrawal Scale (Allsop et al, 2011) is comprised of 19 items for which participants rate 
severity of symptoms in the previous 24 hours. Marijuana Use Summary Sheet/Self-Efficacy 
Questionnaire/Marijuana Problem Scale/Reasons for Quitting Questionnaire: These worksheets, created 
by Stephens and colleagues (2000), will be used to gather information from participants to prepare personalized 
feedback reports (PFRs) for use in the motivational enhancement sessions. DSM-5 Criteria for CUD: DSM-5 
criteria will be assessed at four time points to determine changes in severity of cannabis use disorder. 
 
Safety Assessment. Review of Adverse Events: Adverse events (AEs) will be assessed weekly by study 
personnel. The type of AE, severity of AE, and the relationship to study medication will be recorded. AEs will be 
coded on a weekly basis using Medical Dictionary for Regulatory Activities (MedDRA) rules.  
 
Adherence. During the 12 weeks of treatment, participants will be asked to record and upload twice-daily videos 
of medication-taking at home or in a private location of their choosing.  These videos will be taken remotely and 
submitted via REDCap surveys to confirm medication adherence. Participants may use their personal mobile 
phones for video submission.  If they do not have a smartphone, one will be loaned to them during the first week 
of study. Video submissions may only be completed on a smartphone (cannot be completed on a computer).  A 
survey link will be sent to the participant via text message.  Video capture will occur as part of the REDCap 
survey.  Videos are automatically stored on Android smartphones, and participants will be informed of that so 
they can delete the files, if necessary.  Participants using iPhones (and using loaner iPhones from our group) 
will not have stored videos on their phone and nothing will need to be deleted.  These procedures were used 
successfully in the prior UG3 study.  To complement these procedures, pill counts will be completed at each 
clinic visit during active treatment. 
 
Follow-up plan. Following the study, participants will be referred for appropriate substance use management. 
In the event that an AE occurs during the study, a participant will be followed until resolution. 
Statistical Analysis  
Data Management Plan. All data will be entered into a standard software package (REDCap). Macro programs 
will be written to check the data for logical consistency and values out of possible range. Quarterly database 
management and data integrity audits will be conducted. 
Baseline Analysis. Categorical clinical and demographic variables will be assessed for balance between groups 
with chi-square tests of independence, while continuous variables will be assessed using Student’s t-test.  In 
addition to baseline group differences, preliminary analysis of baseline characteristics with cannabis use 
outcomes of interest will examine significant correlates of use reduction and abstinence.  Characteristics found 
to be significantly associated with cannabis use outcomes will be included as covariates in the initial stages of 
adjusted statistical model development. 
Primary Analysis.  The primary aims for the UH3 portion of the protocol are to test the efficacy and safety of 
varenicline for CUD during a 12-week placebo-controlled trial.  Specific Aim 1: The primary efficacy outcome is 
cannabis use reduction as measured by daily substance use logs and examined as the total number of use 
sessions at each weekly visit (primary interest weeks 6-12).  Group differences in reported session use will be 
examined utilizing a generalized mixed effects models using a log-linear framework for count data.  A Poisson 
distribution will be assumed with a logarithm link function will be used to assess the effects of varenicline 
treatment, time, and the appropriate interaction.  Overdispersion in discrete count models can have a significant 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
impact on parameter inference, thus when detected, a negative binomial distribution will be specified and model 
fit will be compared to the Poisson model.  An offset variable will be included in the models to account for possible 
differences in between visit timing.  Models will be computed both adjusted for design variables and for significant 
covariates and confounders found in the preliminary analysis. Working correlation structures will be 
independently compared using the quasi-likelihood under the independence model criterion statistic (QIC). 
Model based means will be used to construct the pairwise comparisons between groups.  All design adjusted 
models will include baseline average use sessions, study visit, treatment group assignment and randomization 
stratification variables (smoking status and gender). Additional exploratory approaches (e.g., analysis excluding 
participants with <80% medication adherence, per protocol analysis, completers analysis) will be undertaken.  
Specific Aim 2:  We will also compare the frequency of treatment-emergent AEs between treatment groups 
using a non-inferiority analysis. Of particular interest will be AEs leading to medication discontinuation and the 
occurrence of treatment-related serious AEs (SAEs).  We will specifically compare neuropsychiatric AEs and 
suicidality (C-SSRS) ratings by treatment group. We hypothesize that treatment with varenicline will not cause 
undue adverse events and will be non-inferior to the placego group by a margin (δ) of no more than a 10% using 
the Farrington-Manning score test for non-inferiority.   
Exploratory Analysis.  Exploratory Aim 1:  Negative affect will be measured weekly during study treatment and 
compared between groups using generalize linear mixed effects regression models.  Model based means will 
be used to construct the pairwise comparisons between groups and treatment by time interactions will be 
included to assess differential response over time. Exploratory Aim 2:  Further, we will assess the time varying 
relationship between changes in negative affect and cannabis use sessions.  Cross lagged panel models will be 
used to assess the lagged effect of changes in negative affect on cannabis use and visa-versa.  Models will also 
include the autoregressive and synchronous relationships between these variables over time.  Models will 
evaluate the influence of study treatment and medication adherence on the relationship between negative affect 
and cannabis use through the inclusion of time variable and time invariate effects.  If significant treatment effects 
exist, additional stratified analysis will be conducted to elucidate the magnitude and direction of the effect. 
Additional Data Analysis.   Logistic regression models will be used to assess end of study abstinence (7 day 
point prevalence abstinence at week 12 and continuous abstinence from week 6 to 12); primary analysis models 
will be reported both as design adjusted results as well as adjusted for significant clinical covariates.  To 
comprehensively examine the longitudinal efficacy of varenicline, weekly cannabis abstinence will also be 
analyzed over the entire treatment course using generalized linear mixed effects regression models under a 
GEE framework.  Between study visit cannabis use will be based on daily substance use diaries confirmed via 
Time-Line Follow-Back procedures.   The number of treatment visits attended will be compared between groups 
using Poisson regression models, while the number of days retained will be assessed using Cox Proportional 
Hazards regression models. Medication adherence (REDCap video capture of medication-taking; pill counts), 
tobacco smoking status, and gender will be explored as potential moderators of study outcomes through model 
interactions. Craving and withdrawal from cannabis will be assessed between groups over time using 
generalized linear mixed effects models. 
Missing Data and Attrition.  Missing data in longitudinal studies can be a problematic feature but can be mitigated 
through study design considerations. In order to minimize missing data and study attrition, design simplification 
and enhanced communication between study staff and participants will be emphasized.  We will make every 
effort to prevent attrition (e.g., phone/text visit reminders, participation compensation, reinforcing adherence to 
the study protocol).  To assess the potential impact of missing data on the primary study hypothesis, sensitivity 
analysis will be completed (a) with all available data and (b) using methods of multiple imputation (Rubin, 1987).  
Multiple imputation will be implemented using fully conditional specification.  Due to the possibly high rate of 
missing data near the end of the study treatment period (>10%), 100 imputation data files will be created to 
assure reasonable relative efficiency (Von Hippel, 2018). 
Power and Sample Size. The proposed study is powered on the primary efficacy hypothesis that varenicline 
treatment, relative to placebo treatment, will yield reduced cannabis use during the cruicial stages of study 
treatment (weeks 6-12).  The UG3 portion of this study showed a moderate self-reported reduction of weekly 
use days between the varenicline and placebo group (Cohen’s d=0.43).  We intend to improve the granularity of 
this measure by assessing, in more detail, the number of use sessions occurring on a daily basis using daily 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
substance use report logs.  We anticipate the increased information will allow better precision in the estimated 
effect between randomized study groups.  Assuming this, coupled with the more extended 12-week treatment 
compared with the truncated treatment phase in the prior UG3 proof-of-concept trial, results in a slightly 
increased effect size of d=0.5, a high correlation between measures taken over time on the same participant 
(ρ=0.95) and a 5% type 1 error rate, 57 participants are necessary in each treatment arm to achieve adequate 
power (80%).  Additionally, the UG3 noted a higher than expected attrition rate of 35%, thus we anticipate that, 
despite our best efforts and revised approach, attrition during the study could reach 35%.  Thus to ensure that 
we have the appropriate sample, we will enroll and randomize approximately 90 participants per group for a 
total sample size of approximately n=180. This will allow us to detect a difference in cannabis use session of 
at least d=0.5 between randomized study groups while accounting for up to 35% study attrition.  Similar to adult 
varenicline phase III studies (Gonzales et al., 2006), for the primary safety analysis we will compare the 
frequency of all treatment-emergent AEs (defined as any AE occurring between treatment initiation and one 
week following treatment conclusion), SAE’s  between varenicline and placebo groups.  A non-inferiority analysis 
will be utilized (Piaggio et al., 2006).  With an estimated placebo treatment-emergent AE rate of 75% (Gonzales 
et al., 2006), 90% power and two sided α = 0.05, within our proposed sample of approximately 180 randomized 
participants we will be able to detect a 10% non-inferiority margin in AE frequency between treatment groups if 
it exists.   
Design considerations. Comorbid tobacco use disorder. Individuals using both cannabis and tobacco have 
worse cannabis use treatment outcomes. Although data from a large RCT in alcohol using individuals found an 
effect of varenicline on drinking outcomes regardless of tobacco use status (Litten et al., 2013), it is possible that 
a differential effect of varenicline will be found among tobacco and non-tobacco using individuals with CUD. 
Therefore, we propose to stratify randomization on this variable, and to examine comorbid tobacco use as a 
potential moderator in the statistical analysis as well as the impact of varenicline on tobacco use in this 
population. Consideration of gender as a biological variable. In contrast to findings for stimulant drugs, there 
does not appear to be a strong effect of menstrual cycle phase in response to cannabis (for review, see Terner 
and de Wit, 2006).  However, our previous work revealed a significant gender by treatment interaction in 
individuals with CUD, with women randomized to buspirone having fewer negative urine cannabinoid tests than 
women randomized to placebo (p=0.007), and men randomized to buspirone having significantly lower creatinine 
adjusted cannabinoid levels as compared to those randomized to placebo (p=0.023) (McRae-Clark et al., 2015). 
These findings support the need to consider gender as a critical variable in treatment investigations; as such, 
gender will be explored as a potential moderator of treatment response.  
Timeline. Following administrative review, two months are anticipated for transition to the UH3 component to 
allow for study start-up activities. 32 months will be needed for participant recruitment and data collection. The 
final two months will be used for data analysis. At a recruitment rate of approximately five to six participants per 
month (a rate achieved in our prior CUD pharmacotherapy trials), we should meet our target sample size. 
 
PROTECTION OF HUMAN SUBJECTS 
RISKS TO THE SUBJECTS 
a. Human Subjects Involvement and Characteristics 
Admission into the study is open to men and women and to all racial and ethnic groups, age 18 and over. 
Approximately one hundred and eighty individuals (across two participating sites) with cannabis use disorder will 
be recruited primarily through clinical referrals and internet and newspaper advertisements. Inclusion/exclusion 
criteria that apply to all participants are listed below: 
 
Inclusion Criteria  
       •   Must meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days per week  
          in the last 30 days. 
• Express interest in receiving treatment for cannabis use disorder and reducing use. 
• Must be at least 18 years of age.  
• If female and of childbearing potential, must agree to use acceptable methods of birth control for the 
duration of the trial. 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
• Must consent to random assignment, and be willing to commit to medication ingestion. 
• Must be able to read and provide informed consent. 
• Must have body weight >110lbs (50kg) and have BMI between 18 and 35kg/m2 
• Must function at an intellectual level and have knowledge of the English language to sufficiently  allow for 
accurate completion of assessments.. 
Exclusion Criteria 
• Women who are pregnant, nursing, or plan to become pregnant during the course of the study. 
• Individuals with severe renal impairment (creatinine clearance less than 30 mL per minute). 
• Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic disorder.  Stably treated 
MDD, Dysthymia, GAD, Social Phobia, and Specific Phobia diagnoses are acceptable (i.e. same dose of 
medication  has been prescribed for at least 2 months prior to screening and no changes in current 
medication expected during course of the trial). 
• Past year or current posttraumatic stress disorder. 
• Subjects who are actively suicidal, or who report suicidal ideation (SI) with intent or plan in the past year.  
• Past year or current posttraumatic stress disorder. 
• Subjects who are actively suicidal, or who report suicidal ideation (SI) with intent or plan in the past year.  
• Subjects who have a SBQ-R total score ≥8, or for whom the investigator judges that a risk assessment 
by a qualified medical professional is required. Subjects answering ‘yes’ on questions 4 or 5 of C-SSRS 
will be referred to assessment by a qualified mental health professional. 
• Suicidal behavior within the past 10 years or a lifetime history of serious or recurrent suicidal behavior.  
• Subjects who are believed to be at homicidal risk. Concomitant use of psychotropic medications, with the 
exception of stable doses (defined as no dosing adjustments in the past two months) of non-MAO-I 
antidepressants, non-benzodiazepine anxiolytics, and ADHD medications. 
• Current use of medications prescribed for mania or psychosis. 
• Current use of buproprion or nortryptiline. 
• Moderate or severe non-cannabis substance use disorders within the past 60 days with the exception of 
tobacco use disorder. 
• Past year or current moderate or severe alcohol use disorder. 
• Individuals taking an investigational agent within the last 30 days before baseline visit. 
• Individuals with clinically significant medical disorders or lab abnormalities. 
• Any individual at screening with SGOT (AST) or SGPT (ALT) greater than 3 times the upper limit of normal 
and/or total bilirubin greater than two times the upper limit of normal. 
• Individuals with clinically significant cardiovascular disease in the past 6 months (e.g., myocardial 
infarction, CABG, PTCA, severe or unstable angina, serious arrhythmia, or any clinically significant ECG 
conduction abnormality. 
• Individuals with clinically significant cerebrovascular disease in the past 6 months such as TIA, CVA, or 
stroke. 
• Hypersensitivity to varenicline.  
• Individuals who have participated in the clinical trial of any investigative compound within the last 60 days. 
• Individuals who are on probation or under a mandate to obtain treatment. 
• Individuals with plans to initiate or change frequency of attendance at self-help meetings (e.g. AA, NA). 
 
b. Sources of Materials 
Research material obtained from individual participants includes questionnaires and in-person and remote 
interviews with study personnel, and blood and urine samples. To ensure confidentiality, all participant data will 
be letter/number coded, and only the investigators will have access to the master lists of codes. The research 
material will be obtained specifically for research purposes.  Written research material obtained will be stored in 
the Addiction Sciences Division at MUSC or at Behavioral Health Services of Pickens County in Pickens, SC, in 
an office that is locked when not in use. Urine samples from MUSC site will be stored in the Clinical Neurobiology 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
Urine samples from the Pickens site will be stored at Behavioral Health Services of Pickens County and then 
sent to MUSC CNL for analysis in batches.  
 
c. Potential Risks 
The varenicline package insert details adverse events associated with the medication. Specifically, it reports that 
“the most common adverse reactions (>5% and twice the rate seen in placebo-treated patients) were nausea, 
abnormal (e.g., vivid, unusual, or strange) dreams, constipation, flatulence, and vomiting.” Meta-analyses of the 
four main adverse events in varenicline versus placebo groups in adult trials yielded relative risks (RRs) of 3.21 
(95% CI 2.71, 3.80) for nausea, 1.50 (95% CI 1.26, 1.79) for insomnia, 2.79 (95% CI 2.09, 3.72) for abnormal 
dreams, and 1.20 (95% CI 1.00, 1.45) for headache (Cahill et al., 2009). While post-marketing anecdotal reports 
of psychiatric adverse events led to an FDA “black box” warning for varenicline, a reanalysis of controlled trials 
revealed no evidence that varenicline is associated with neuropsychiatric adverse events (Thomas et al., 2015). 
There is a potential risk of loss of confidentiality.  
 
ADEQUACY OF PROTECTION AGAINSTS RISKS  
a. Recruitment and Informed Consent 
Participants will primarily be recruited through clinical referrals and the use of advertisements (internet, 
newspaper). Medical records will not be reviewed to identify potential study participants unless patients have 
requested to be contacted through a research permissions registry.  A study PI, Co-I, or other qualified study 
staff will obtain informed consent. The informed consent form includes a detailed description of the study 
procedures, along with statements regarding participants’ rights to withdraw from the procedure at any time 
without consequences. The informed consent form will be explained to participants in easy-to-understand 
language, and participants will be instructed to read the form carefully prior to signing it.  Consent will be 
documented by the signature of the participant on the informed consent agreement, accompanied by the 
signature of the individual obtaining the consent. 
 
b. Protections Against Risks 
All study participants will be closely monitored for psychiatric and medical stability. All study procedures will be 
conducted under the supervision of experienced personnel. If crisis intervention is necessary during screening 
or study enrollment, senior staff will be available to evaluate the subject and provide an intervention or referral. 
In regards to suicidality, any participant endorsing suicidality on the C-SSRS (either during screening or at a 
subsequent study visit) will be assessed for safety by a psychiatrist or other qualified licensed clinician.  If 
hospitalization is indicated, the patient will be hospitalized through MUSC or Behavioral Health Services of 
Pickens County, or an appropriate referral will be made. All participants will be fully informed that they may 
withdraw from the study at any time without penalty.  
 
To ensure confidentiality, all participant data will be coded by name and/or numbers, and only the investigators 
will have access to the master lists of codes.  In specific instances, participant PHI may be available to other 
entities, such as for ClinCard registration/payment purposes.  All participant records will be kept in a locked 
cabinet in an office that will be locked at times when not in use. The research staff understands the importance 
of maintaining confidentiality, and this method of maintaining confidentiality has been used for several years by 
our research group and has been effective. All electronic databases are stored on HIPAA-compliant servers with 
restricted access. RedCap video clips will only be viewed by approved research staff and will be deleted when 
the study has ended and data analysis is complete. All co-investigators and study personnel have completed (or 
will complete upon hiring) training in Good Research Practices as mandated by the MUSC IRB.  
 
Participants will be taught about potential side effects of varenicline and will be closely followed by psychiatrists, 
physicians, a PharmD, a NP, and other members of the research team. Pregnancy tests will be performed prior 
to medication initiation and monthly during the study. Participants will be excluded if they have a known 
hypersensitivity to varenicline. Adverse events will be assessed at each clinic visit, and all participants will be 
provided with an after-hours emergency contact number in the event that an adverse event occurs when the 
clinic is closed.  
 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
POTENTIAL BENEFITS OF THE PROPOSED RESEARCH TO THE SUBJECT AND OTHERS 
Possible risks to study participants include adverse reactions to varenicline. Benefits include detailed 
assessment of cannabis use and receipt of a medication and medication management that may help reduce 
cannabis use. The minimal risks are reasonable in relation to the potential benefits to be gained from the 
investigation.    
 
IMPORTANCE OF THE KNOWLEDGE TO BE GAINED 
This study may help accelerate approval of varenicline for treatment of cannabis use disorder. Presently, there 
are no FDA-approved medications for cannabis use disorder. The moderate risks of the investigation are 
considered reasonable in relation to the expected knowledge to be gained.   
 
CLINICALTRIALS.GOV REQUIREMENTS 
In accordance with Public Law 110-85, this project will be registered at the ClinicalTrials.gov Protocol 
Registration System Information Website prior to study initiation. 
 
 


Program Director/Principal Investigator (Last, First, Middle):  McRae-Clark, Aimee, L. 
 
 
 
            V12 10. 5.2022 
 
REFERENCES 
Allsop, D. J., Norberg, M. M., Copeland, J., Fu, S., & Budney, A. J. (2011). The Cannabis Withdrawal Scale 
development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend, 119, 
123-129. 
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., Watsky, E. J., Gong, J., Williams, 
K. E., Reeves, K. R., & Varenicline Phase 3 Study, G. (2006). Varenicline, an alpha4beta2 nicotinic 
acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking 
cessation: a randomized controlled trial. JAMA, 296, 47-55. 
Heishman, S. J., Evans, R. J., Singleton, E. G., Levin, K. H., Copersino, M. L., & Gorelick, D. A. (2009). Reliability 
and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend, 102, 35-40. 
Heishman, S. J., Singleton, E. G., & Liguori, A. (2001). Marijuana Craving Questionnaire: development and initial 
validation of a self-report instrument. Addiction, 96, 1023-1034. 
Huestis, M. A., & Cone, E. J. (1998). Differentiating new marijuana use from residual drug excretion in occasional 
marijuana users. J Anal Toxicol, 22, 445-454. 
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, 
D. A., Sarid-Segal, O., Kampman, K., Brunette, M. F., Strain, E. C., Tiouririne, N. A., Ransom, J., Scott, 
C., Stout, R., & Group, N. S. (2013). A double-blind, placebo-controlled trial assessing the efficacy of 
varenicline tartrate for alcohol dependence. J Addict Med, 7, 277-286. 
McRae-Clark, A. L., Baker, N. L., Gray, K. M., Killeen, T. K., Wagner, A. M., Brady, K. T., DeVane, C. L., & 
Norton, J. (2015). Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. 
Drug Alcohol Depend, 156, 29-37. PMCID: PMC4633378 
Osman A., Bagge C.L., Guitierrez P.M., Konick L.C., Kooper B.A., Barrios F.X. (2001). The Suicidal Behaviors 
Questionnaire Revised (SBQ-R): Validation with clinical and nonclinical samples. Assessment, 5, 443-
454. 
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J., & Group, C. (2006). Reporting of 
noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA, 295, 
1152-1160. 
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. 
A., Greenhill, L., Shen, S., & Mann, J. J. (2011). The Columbia-Suicide Severity Rating Scale: initial 
validity and internal consistency findings from three multisite studies with adolescents and adults. Am J 
Psychiatry, 168, 1266-1277. 
Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987. 
Schwilke, E. W., Gullberg, R. G., Darwin, W. D., Chiang, C. N., Cadet, J. L., Gorelick, D. A., Pope, H. G., & 
Huestis, M. A. (2011). Differentiating new cannabis use from residual urinary cannabinoid excretion in 
chronic, daily cannabis users. Addiction, 106, 499-506. 
Sheehan, D. V., & Lecrubier, Y. (2003). Mini International Neuropsychiatric Interview. 5.0.0, DSM-IV. In. 
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., & 
Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and 
validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 59, 
22-33;quiz 34-57. 
Sobell, L. C., & Sobell, M. B. (1992). Timeline follow-back: A technique for assessing self-reported ethanol 
consumption. In J. Allen & R. Z. Litten (Eds.), Measuring alcohol consumption: Psychological and 
biological methods (pp. 41-72). Totowa, NJ: Humana Press. 
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000). Comparison of extended versus brief treatments for 
marijuana use. J Consult Clin Psychol, 68, 898-908. 
Terner, J. M., & de Wit, H. (2006). Menstrual cycle phase and responses to drugs of abuse in humans. Drug 
Alcohol Depend, 84, 1-13. 
von Hippel PT. How many imputations do you need? A Two-stage calculation using a quadratic rule. Sociol 
Methods Res. 2018 
Zevin, S., Jacob, P., Geppetti, P., & Benowitz, N. L. (2000). Clinical pharmacology of oral cotinine. Drug Alcohol 
Depend, 60, 13-18. 
 

ICF_000.pdf: 
Page 1 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
Medical University of South Carolina 
 
CONSENT TO BE A RESEARCH SUBJECT 
 
Varenicline for the Treatment of DSM 5 Cannabis Use Disorder in Adults 
 
You are being asked to volunteer for a research study. Research studies are voluntary 
and include only people who choose to take part.  The purpose of this study is to evaluate 
the safety and effectiveness of varenicline (sometimes known as Chantix) compared to 
placebo (an inactive substance) in the treatment of Cannabis Use Disorder. Varenicline 
is not FDA approved for treatment of Cannabis Use Disorder. 
 
If you agree to participate, you will undergo a screening process where you will have a 
psychiatric and substance use assessment, a medical history taken, and blood drawn to 
assess your health.  If your test results show you are able to continue, you will be 
randomly assigned to receive either varenicline or placebo.  You will have a 50:50 chance 
of being on varenicline (like the flip of a coin).  Neither you nor your study doctor will know 
what group you are in.  You will take the study medication twice a day for 12 weeks, and 
will have study visits once a week for those 12 weeks, with 1 follow up visit a week after 
that, so that the total duration you are in the study will be approximately 14 weeks. You 
will be asked to complete questionnaires about substance use at each visit. Urine will be 
sampled weekly.  
 
There are risks to the study drug that are described in this document.  An example of a 
risk is nausea (upset stomach).  If you are randomized to placebo, you will go without 
treatment for your condition for 12 weeks.   Also with randomization, neither you nor your 
doctor will decide to what group you are assigned.    If you have a strong opinion about 
what treatment you receive or would like your doctor to decide what treatment you 
receive, you should not participate in this study. 
 
It is unknown if varenicline will help your condition, however you will be followed closely 
with weekly visits, and you can stop participating in the study at any time.  It is possible 
that your symptoms will improve, but that cannot be guaranteed.  You do not have to 
participate in this study to have your condition treated.  Alternative treatments include 
special counseling and other therapies. 
 
If you are interested in learning more about this study, please continue to read below. 
 
A. PURPOSE OF THE RESEARCH: 
You are being asked to volunteer for a research study designed to evaluate the effects of 
a medication (varenicline) to help people quit using cannabis.  
 
Please read this consent form carefully and take your time making your decision. As your 
study doctor or study staff discusses this consent form with you, please ask him/her to 


Page 2 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
explain any words or information that you do not clearly understand.  To confirm your 
understanding, you will be asked to complete a consent quiz before signing this form.  
 
You are being asked to participate in this study because you use cannabis regularly. The 
study is sponsored by the National Institute on Drug Abuse. The investigators in charge 
of this study at MUSC are Aimee McRae-Clark, PharmD, and Kevin Gray, MD. The study 
is being done at 2 sites. Approximately 174 people will take part study-wide and 
approximately 87 will take part at this institution. 
 
B. PROCEDURES: 
If you agree to be in this study, you will first be evaluated and the results of the evaluation 
must meet entrance requirements. This first evaluation will include psychiatric interviews, 
an assessment of your alcohol and drug use, and a medical history. You will have blood 
drawn (about 2 teaspoons) to assess your general health.  You may be asked to meet 
with medical staff at your randomization visit for a physical exam if they think it is 
necessary based on your medical history or bloodwork. You may be asked to provide a 
urine sample to test for drugs of abuse. If you are female and of child-bearing potential, 
you will have a pregnancy test prior to urine drug screening. You will be asked to fill out 
several forms dealing with how often and why you use marijuana, your mood symptoms, 
and sleep quality, either in the clinic or via a survey link.  
This initial evaluation visit may also be done remotely. In that case, the consent will be 
emailed to you prior to the screening appointment. You will be asked to find a private 
location to have a video call with study staff. On the video call, study staff will obtain 
informed consent and do the initial interview. You will also speak with study medical staff 
to review your medical history. You may be asked to meet with medical staff at your 
randomization visit for a physical exam if they think it is necessary based on your history. 
If determined eligible after your video call, you will be asked to have your blood drawn to 
assess general health, and test for pregnancy if female (either at MUSC, LabCorp or 
AnMed, depending on your location). You will be sent online survey links to complete 
questionnaires.  
If you meet all entrance requirements, you will come to the clinic for a randomization visit.  
At this visit you will be asked to provide a urine sample to test for drugs of abuse and 
nicotine.  You will also complete assessments regarding marijuana use and mood, and 
you will receive study medication, either varenicline or placebo (a capsule that does not 
contain any active medication). Neither you nor the study staff will know which medication 
you are taking as both varenicline and placebo will be given as capsules identical in 
appearance. You will be randomly assigned to receive either varenicline or placebo. This 
means that you have a 50/50 chance (like flipping a coin) of being in either group. Neither 
the researchers nor you will make the choice regarding to which group you are assigned. 
The medication will be provided at the standard recommended dose of 0.5mg daily for 
three days, then 0.5mg twice daily for four days, and then 1mg twice daily for the 
remainder of the twelve-week treatment period.  


Page 3 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
You will be required to take your medication twice daily while enrolled in this study.  You 
are asked to take one capsule at 8:00AM each morning and the other at 8:00PM each 
evening.   
 
You will also be asked to record and upload a video of yourself taking your morning and 
evening medication to research staff using a smartphone and a secure web application.  
When uploading the morning medication video, you will also be asked to complete a 
survey regarding your marijuana use the previous day. You will be trained on how to do 
this at your randomization visit.  If you do not have a smartphone or do not wish to use 
your own, we will provide one to you for the duration of the study.  If you use an Android 
smartphone, your medication videos may be automatically stored on your phone prior to 
sending them, thus you will need to delete each video file from your phone. If preferred, 
the daily substance use reports can be completed on a computer.   
You will have weekly study visits for twelve weeks.  At these visits, you may be asked to 
fill out forms and answer specific questions concerning your substance use, mood 
symptoms, and your feelings in general, either in clinic or via survey link. Your urine will 
be tested at each visit to check for drugs of abuse and nicotine. If you are female, you will 
be screened for pregnancy monthly.  In some extenuating instances, such as in the case 
of a pandemic, your weekly study visits and procedures may be conducted remotely via 
a telehealth platform, and/or in-person visits may be limited to less than weekly. 
You will be required to complete one follow-up visit approximately one week after you 
finish study procedures.  
 
We may ask you to identify an individual who can be contacted to help locate you if 
needed. A family member or a significant other/spouse is preferred. You will need to sign 
a release of information form to allow the study team to contact the individual. 
 
Participation in this study is totally voluntary, and you may choose not to participate. You 
may also withdraw your consent and discontinue participation at any time. Discontinuation 
will in no way jeopardize your ability to receive treatment at this Institution now or in the 
future. You may be withdrawn from the study without your consent if the researchers 
believe it is in your best interest. 
 
C. DURATION: 
Participation in this study involves approximately 16 visits over a period of about three 
months. The initial screening visits will take between 1 and 2 hours each.  The rest of the 
visits will take approximately 30-60 minutes each.   
 
D. RISKS/DISCOMFORTS: 
Participation in this study may involve risks. There may be risks and side effects that are 
not known at this time.  Possible risks from study participation include: 
 


Page 4 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
Risks associated with varenicline: The most commonly observed side effects 
associated with varenicline treatment (incidence > 5% and at least twice the rate of 
placebo) are nausea, abnormal (e.g., vivid, unusual, or strange) dreams, constipation, 
flatulence, and vomiting. In individuals with major depressive disorder and other 
psychiatric disorders, medications like varenicline may increase suicidal thoughts and 
behavior in children, adolescents, and young adults.  Watch for these changes, and 
inform the study staff immediately if you notice new or sudden changes in mood, behavior, 
actions, thoughts, or feelings, especially if severe.  
 
Risks associated with screening/assessment: The interviews that you will undergo at 
screening involve no specific risks or discomforts beyond those of a standard clinical 
interview situation, such as feeling upset at the review of your psychiatric status, 
boredom, or fatigue. If a question makes you feel uncomfortable you may refuse to 
answer it. 
 
Risk of loss of confidentiality: There is a risk of a loss of confidentiality as a result of 
participation in this study. Information about you, as well as your image, will be kept in 
password-protected databases and computers or a locked research clinic area, and will 
only be accessible by the principal investigator and the research staff. Video clips will only 
be viewed by approved research staff. Those video clips will be deleted when the study 
has ended and data analysis is complete. In order to ensure confidentiality, all participant 
information (questionnaires and identifying information) will be identified only by your 
name and/or a code number and kept under lock and key and in password-protected 
databases.  
 
Risks associated with blood drawing: The risks of drawing blood include temporary 
discomfort from the needle stick, bruising, and infection. Fainting could occur. 
 
Additional risks: You will be assigned to treatment by chance. The treatment you receive 
may prove to be less effective or to have more side effects than the other study treatment 
or other available treatment. If you are in the group that receives placebo, you will not 
receive active medication. 
 
Unknown risks: The experimental treatments may have unknown side effects. The 
researchers will let you know if they learn anything that might make you change your mind 
about participating in the study. 
 
If you are a female of childbearing potential, you will receive a pregnancy test, and if 
pregnant, you will not be allowed to participate in the study. If you are capable of 
becoming pregnant, you must be using a medically approved method of birth control 
(such as contraceptive pills, diaphragms, or other forms of barrier contraceptives) and 
you must continue to do so during the course of the study. Should you become pregnant 
during the study you must immediately contact your study doctor and discontinue 
treatment since the risk to your baby due to varenicline is unknown.  


Page 5 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
Your urine will be screened for the presence of marijuana and other potentially abused or 
illegal drugs. These results will not be part of your medical record but will be kept in 
research records maintained by the investigator. Every effort will be made to protect the 
confidential nature of this information. However, there may be circumstances under which 
the investigator may release this information. If you are pregnant or become pregnant 
and test positive for illegal drugs, the SC Department of Social Services (DSS) may be 
notified. You could be at risk of going to jail or losing custody of your children. 
 
E.  CERTIFICATE OF CONFIDENTIALITY 
This research is covered by a Certificate of Confidentiality from the Federal government. 
This means that the researchers may not disclose information or biospecimens that may 
identify you, even by a court subpoena, in any federal, state, or local civil, criminal, 
administrative, legislative, or other proceedings, nor can the information or biospecimens 
be used as evidence, unless you have consented to this disclosure. Information or 
biospecimens protected by this Certificate cannot be disclosed to anyone else who is not 
connected with the research unless you have consented to the disclosure.  More 
specifically, identifiable information or biospecimens will not be shared with your medical 
providers who are not involved in this research unless you authorize the study to disclose 
information to them, or if it is used for other scientific research, as allowed by federal 
regulations protecting research subjects. 
Information about your study participation will not be in your MUSC medical record.  This 
means that neither your research participation nor any of your research results will be 
included in any MUSC medical record.  A Certificate of Confidentiality does not prevent 
you from voluntarily releasing information about yourself or your involvement in this 
research.  If you want your research information released to an insurer, medical care 
provider, or any other person not connected with the research, you must authorize the 
researchers to release it. 
The Certificate of Confidentiality will not be used to prevent disclosure as required by 
federal, state, or local law.  Examples of required disclosure include: child abuse and 
neglect, threat of harm to self and others, but there could be others. 
Finally, a Certificate may not be used to withhold information from the Federal 
government needed for auditing or evaluating Federally funded projects or information 
needed by the FDA. 
F. BENEFITS: 
You may receive a medication that may be effective in reducing your marijuana use. Of 
course, this cannot be guaranteed or promised. The results of this study may also benefit 
other patients who might later be treated with the same medicine.  
G. COSTS: 
If you choose to use your own smartphone to upload your daily medication videos, any 
cellular data and usage rates assessed by your carrier will apply. 


Page 6 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
H. PAYMENT TO PARTICIPANTS: 
In return for your time and effort, you will receive $50 for completing the screening visits 
($25 for the interview and $25 for the bloodwork). You will be compensated $50 for the 
End of Treatment visit (Week 12).  If you receive a study smartphone but do not return it 
at this End of Treatment visit, you will receive $25 for attending the EOT visit (versus 
$50).  You will receive $50 for all other weekly clinic visits and the follow up visit.  
Therefore, you could earn up to $750 if you complete all study visits. You will also receive 
$2.50 for each uploaded morning medication video and survey and $2.50 for each 
evening medication video- videos and surveys must be complete to receive this 
compensation. Your total overall compensation for study participation and procedures will 
depend on how many visits you attend, how many surveys and videos you upload, and if 
you return a borrowed smartphone. Lost or stolen iPhones may be reported to the federal 
funding agency. 
 
Payment for study visits will be made using a pre-paid debit card, called a ClinCard. It 
works like a bank debit card and you may use the card to purchase goods or services 
everywhere Debit MasterCard is accepted. You will be given or mailed a ClinCard at the 
beginning of the study.  Each time you receive payment for participation in this study, the 
money will be added to the card, as outlined in the payment schedule below.  Details of 
the debit card system are explained on an additional sheet.  
 
Payments that you receive from MUSC for participating in a research study are 
considered taxable income per IRS regulations.  Payment types may include, but are not 
limited to: checks, cash, gift certificates/cards, personal property, and other items of 
value.  If the total amount of payment you receive from MUSC reaches or exceeds 
$600.00 in a calendar year, you will be issued a Form 1099. 
 
I. ALTERNATIVES: 
There are alternative treatments for marijuana use. These include special counseling and 
other therapies (such as twelve step groups and classes on relapse prevention) aimed at 
decreasing substance use. You may also choose not to participate. 
J. DATA SHARING 
Information about you (including your identifiable private information and/or any 
identifiable biospecimens) may have all of your identifiers removed and used for future 
research studies or distributed to other researchers for future research without additional 
informed consent from you or your legally authorized representative. 
 
K. DISCLOSURE OF RESULTS 
If, for any reason, you would like your medical records released to anyone other than the 
investigators, you will be asked to sign an additional release of information form. 


Page 7 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
L. AUTHORIZATION TO USE AND DISCLOSE (RELEASE) MEDICAL INFORMATION 
As part of this research study, your study doctor and his/her research team will keep 
records of your participation in this study. 
 
The health information MUSC may use or disclose (release) for this research study 
includes information in your medical record, results of physical exams, medical history, 
lab tests or certain health information indicating or relating to your condition.  
 
Your study doctor and his/her research team will use and disclose (release) your health 
information to conduct this study. The health information listed above may be used by 
and/or disclosed (released) to the following, as applicable: 
 
• 
The sponsor of the study including its agents such as data repositories or 
contract research organizations monitoring the study; 
• 
Other institutions and investigators participating in the study; 
• 
Other investigators within the Addiction Sciences Division conducting similar 
research studies; 
• 
Data Safety Monitoring Boards; 
• 
LabCorp 
• 
AnMed 
• 
Accrediting agencies; 
• 
Clinical staff not involved in the study whom may become involved if it is 
relevant; 
• 
Parents of minor children if less than 16 years old.  Parents of children 16 years 
old or older require authorization from the child; or 
• 
Health insurer or payer in order to secure payment for covered treatment; 
• 
Federal and state agencies and MUSC committees having authority over the 
study such as: 
 
o The Institutional Review Board (IRB) overseeing this study;  
Committees with quality improvement responsibilities;  Office of 
Human Research Protections; Food and Drug Administration;  
National Institutes of Health or Other governmental offices, such as 
a public health agency or as required by law. 
 
Those persons who receive your health information may not be required by Federal 
privacy laws (such as the Privacy Rule) to protect it and may share your information with 
others without your permission, if permitted by laws governing them.   You do not have to 
sign this consent form.  If you choose not to sign, it will not affect your treatment, payment 
or enrollment in any health plan or affect your eligibility for benefits.  However, you will 
not be allowed to be a participant in this research study. 
 
You will be given a copy of this consent form.  Your authorization will expire at the 
conclusion of this study or, if you are participating in a study designed for the development 


Page 8 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
of a drug or device, your authorization will remain in effect until the drug or device is 
approved by the FDA or until the company’s application to study the drug/device is 
withdrawn.   You have the right to withdraw your agreement at any time.  You can do this 
by giving written notice to your study doctor.  If you withdraw your agreement, you will not 
be allowed to continue participation in this research study.  However, the information that 
has already been collected will still be used and released as described above.  You have 
the right to review your health information that is created during your participation in this 
study.  After the study is completed, you may request this information. 
 
Your health information will be used or disclosed when required by law.  Your health 
information may be shared with a public health authority that is authorized by law to collect 
or receive such information for the purpose of preventing or controlling disease, injury or 
disability and for conducting public health surveillance, investigations or interventions.  No 
publication or public presentation about the research study will reveal your identity without 
another signed authorization from you.   
 
If you have questions or concerns about this Authorization or your privacy rights, please 
contact MUSC’s Privacy Officer at (843) 792-8740.   
 
Regulations require that you be given a copy of the MUSC Notice of Privacy Practices 
(NPP) describing the practices of MUSC regarding your health information. One can be 
found at the end of this form. 
 
M. RECRUITMENT OF SUBJECTS: 
You are invited to participate in the recruitment of other subjects for this study. If you 
choose to participate, we will provide you with coupons that you may give to other people 
(e.g., peers, acquaintances) who you think would be eligible and interested in this study. 
You may choose to tell people to whom you give these coupons to call the study office if 
they are interested in participating in the study. These individuals will not be identified 
unless they contact the study office themselves. If any of your coupons result in 
successful study recruitment, you will receive $20 for each one. Participation in the 
recruitment process is completely voluntary, and if you elect not to participate your 
participation in this study will not be affected in any way. 
 
N. NEW INFORMATION: 
If there are any significant new findings during the course of the study, you will be notified. 
 
O. STUDENT PARTICIPATION: 
Your participation or discontinuance will not constitute an element of your academic 
performance nor will it be part of your academic record at this Institution. 
 
P. EMPLOYEE PARTICIPATION: 
Your participation or discontinuance will not constitute an element of your job 
performance or evaluation nor will it be a part of your personnel record at this institution. 


Page 9 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
Q. INVITATION TO PARTICIPATE IN FUTURE STUDIES: 
From time to time we have other research studies that you may be eligible to participate 
in. We are inviting you to allow us to contact you by phone, mail, or both to see if you 
would be interested in participating in any future studies. By initialing the “yes” line below, 
you are indicating that you would like to give us your phone number, any alternate phone 
numbers, and address so that we may contact you if another study becomes available 
that you might qualify for. To maintain your confidentiality, we will not leave 
identifiable messages or any identifiable information on letters or envelopes that 
are mailed to you.  By checking the “no” box below, you are indicating that you do not 
want study personnel to contact you for any future studies. You may still participate in the 
current study if you initial “no” and you will not suffer any adverse consequences in doing 
so.  
 
_______Yes. I would like to be re-contacted for future studies. I give permission for 
study personnel to contact me by phone or by mail to inform me of other available 
studies I may be eligible for.  
    
 _______No. I do not wish to be re-contacted for any future studies.  
 
 
R. CLINICAL TRIALS REGISTRY: 
A description of this clinical trial will be available on www.ClinicalTrials.gov as required by 
U.S. law.  This website will not include information that can identify you.  At most, the 
website will include a summary of the results.  You can search this website at any time. 
 
Results of this research will be used for the purposes described in this study. This 
information may be published, but you will not be identified. Information that is obtained 
concerning this research that can be identified with you will remain confidential to the 
extent possible within State and Federal law. The sponsor and the Food and Drug 
Administration (FDA) will receive copies of the research records. The investigators 
associated with this study, employees of the sponsor, the FDA, and the MUSC 
Institutional Review Board for Human Research will have access to identifying 
information. All records in South Carolina are subject to subpoena by a court of law. 
 
In the event of a study related injury, you should immediately go to the emergency room 
of the Medical University Hospital, or in case of an emergency go to the nearest hospital, 
and tell the physician on call that you are in a research study. They will call your study 
doctor who will make arrangements for your treatment. If the study sponsor does not pay 
for your treatment, the Medical University Hospital and the physicians who render 
treatment to you will bill your insurance company. If your insurance company denies 
coverage or insurance is not available, you will be responsible for payment for all 
services rendered to you. 


Page 10 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
Your participation in this study is voluntary. You may refuse to take part in or stop taking 
part in this study at any time. You should call the investigator in charge of this study if you 
decide to do this. The data collected on you to this point remains part of the study 
database and may not be removed. Your decision not to take part in the study will not 
affect your current or future medical care or any benefits to which you are entitled. 
 
The investigators and/or the sponsor may stop your participation in this study at any time 
if they decide it is in your best interest. They may also do this if you do not follow the 
investigator’s instructions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Page 11 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
Volunteers Statement 
 
I have been given a chance to ask questions about this research study. These questions 
have been answered to my satisfaction. If I have any more questions about my 
participation in this study or study related injury, I may contact Aimee McRae-Clark, 
PharmD. I may contact the Medical University of SC Patient and Family Care Liaison 
(843) 792-5555 concerning medical treatment. 
 
If I have any questions, problems, or concerns, desire further information or wish to offer 
input, I may contact the Medical University of SC Institutional Review Board for Human 
Research IRB Manager or the Office of Research Integrity Director at (843) 792-4148. 
This includes any questions about my rights as a research subject in this study. 
 
I agree to participate in this study. I have been given a copy of this form for my own 
records. 
 
 
 
Signature of Person Obtaining Consent               Date  
 
                                                                            ________________________________  
Signature of Participant                                 Date     *Name of Participant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Page 12 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Page 13 of 13                                                                                      Version 2.10.2022 
 
IRB Number: Pro00089933 
Date Approved 2/15/2022